Strand Therapeutics Announces Poster Presentation on STX-001 at the 2023 AACR Annual Meeting

BOSTON--(BUSINESS WIRE)--#AACR2023--Strand Therapeutics, the programmable mRNA company developing curative therapies for cancer and other diseases, today announced the details of its poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2023, being held from April 14 - 19, 2023 in Orlando, Florida.

Strand will present preclinical data from its lead programmable mRNA candidate STX-001, a multi-modal synthetic self-replicating mRNA technology that delivers a prolonged and locally-acting IL-12 cytokine to the tumor microenvironment. STX-001, when delivered directly to the tumor, induces a highly immunogenic tumor cell death while the mRNA-encoded IL-12 payload promotes recruitment of effector T cells and NK cells into the tumor microenvironment.

Details of the presentation are as follows:

Presentation Title: STX-001, a locally administered LNP-formulated self-replicating mRNA that encodes the therapeutic payload IL-12, induces deep systemic immune responses to solid tumors

Session Category: Experimental and Molecular Therapeutics

Session Title: Gene and Vector-based Therapy

Session Date and Time: Monday Apr 17, 1:30 PM - 5:00 PM ET

Location: Orange County Convention Center, Orlando, Florida, Poster Section 16

Poster Board Number: 2

Permanent Abstract Number: 2731

The full text of the abstract will be published to the AACR Online Program Planner at 4:30 PM ET on Tuesday, March 14. The abstract will also be published in an online-only supplement to the AACR journal Cancer Research on Friday, March 31. Additional meeting information is available on the AACR website.

About Strand Therapeutics

Strand Therapeutics is a next-generation biotechnology company committed to transforming the lives of patients by developing first-in-class programmable mRNA therapeutics. Founded by leaders in mRNA-based synthetic biology at MIT, Strand is creating the first platform for programmable, long-acting mRNA therapeutics that are bioengineered to enable precise control of the location, timing, intensity, and duration of therapeutic activity. Strand’s mission is to develop improved treatment options for cancer and other life-threatening diseases. The company is headquartered in Boston, MA. For more information, visit www.strandtx.com. Follow us on Twitter @StrandTx.

Kimberly Ha
KKH Advisors
917-291-5744
kimberly.ha@kkhadvisors.com